ATE205396T1 - Verwendung von menschlichem protein c zur verhinderung und behandlung von ablagerungen von thrombocyten - Google Patents

Verwendung von menschlichem protein c zur verhinderung und behandlung von ablagerungen von thrombocyten

Info

Publication number
ATE205396T1
ATE205396T1 AT94109293T AT94109293T ATE205396T1 AT E205396 T1 ATE205396 T1 AT E205396T1 AT 94109293 T AT94109293 T AT 94109293T AT 94109293 T AT94109293 T AT 94109293T AT E205396 T1 ATE205396 T1 AT E205396T1
Authority
AT
Austria
Prior art keywords
human protein
thrombocyte
deposits
treat
prevent
Prior art date
Application number
AT94109293T
Other languages
English (en)
Inventor
Johann Dr Eibl
Hans-Peter Schwarz
Miguel Lozano-Molero
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of ATE205396T1 publication Critical patent/ATE205396T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT94109293T 1993-06-18 1994-06-16 Verwendung von menschlichem protein c zur verhinderung und behandlung von ablagerungen von thrombocyten ATE205396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4320294A DE4320294A1 (de) 1993-06-18 1993-06-18 Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen

Publications (1)

Publication Number Publication Date
ATE205396T1 true ATE205396T1 (de) 2001-09-15

Family

ID=6490672

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0119394A AT407704B (de) 1993-06-18 1994-06-15 Verwendung von humanem protein c zur verhinderung und behandlung von thrombozytenablagerungen
AT94109293T ATE205396T1 (de) 1993-06-18 1994-06-16 Verwendung von menschlichem protein c zur verhinderung und behandlung von ablagerungen von thrombocyten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0119394A AT407704B (de) 1993-06-18 1994-06-15 Verwendung von humanem protein c zur verhinderung und behandlung von thrombozytenablagerungen

Country Status (14)

Country Link
US (1) US5614493A (de)
EP (1) EP0629407B1 (de)
JP (1) JP3106059B2 (de)
AT (2) AT407704B (de)
AU (1) AU680894B2 (de)
CA (1) CA2126135C (de)
CZ (1) CZ148294A3 (de)
DE (2) DE4320294A1 (de)
DK (1) DK0629407T3 (de)
ES (1) ES2162829T3 (de)
FI (1) FI942941A7 (de)
HU (1) HU217609B (de)
NO (1) NO942298L (de)
SK (1) SK282358B6 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806966D0 (en) * 1998-03-31 1998-06-03 Ppl Therapeutics Scotland Ltd Bioloically modified device
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
ES2618899T3 (es) * 2010-02-26 2017-06-22 The Children's Hospital Of Philadelphia Zimógeno de proteína C y procedimientos de utilización del mismo para prevenir las metástasis del cáncer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT218391B (de) 1959-01-26 1961-11-27 Anton Daxboeck Vorrichtung zur Sicherung einer Türschloßfalle, insbesondere für Kraftfahrzeuge
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
EP0035204B2 (de) * 1980-03-05 1991-05-22 Miles Inc. Pasteurisierte therapeutisch aktive Proteinzusammensetzungen
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4480029A (en) * 1981-04-27 1984-10-30 Baxter Travenol Laboratories, Inc. Biological indicators and their use
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
US4585654A (en) * 1983-04-29 1986-04-29 Armour Pharmaceutical Co. Process for pasteurizing fibronectin
EP0124506B1 (de) * 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4589495A (en) * 1984-04-19 1986-05-20 Weatherford U.S., Inc. Apparatus and method for inserting flow control means into a well casing
DE3432083A1 (de) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
DE3688900T3 (de) * 1985-06-27 1998-06-10 Univ Washington Expression von Protein C.
DE3544663A1 (de) * 1985-12-13 1987-06-19 Schering Ag Thrombosebehandlung mit fibrinolytika und prostacyclinen
JPH0662436B2 (ja) * 1986-05-19 1994-08-17 株式会社ミドリ十字 静注用免疫グロブリン製剤の製造方法
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
EP0287028B1 (de) * 1987-04-17 1993-07-21 Teijin Limited Verfahren zur Trennung von aktiviertem menschlichem Protein C
WO1988008710A1 (en) * 1987-05-15 1988-11-17 Rubinstein Alan I Sequential improved method for treatment of human blood-clotting factor products
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
GB8721951D0 (en) * 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
AT391809B (de) * 1988-01-12 1990-12-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutplasmaprodukten
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
ES2053619T3 (es) * 1988-05-27 1994-08-01 Centre Regional De Transfusion Procedimiento para la fabricacion de un factor antihemofilico de gran pureza y libre de virus mediante cromatografia.
AT397203B (de) * 1988-05-31 1994-02-25 Immuno Ag Gewebeklebstoff
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
DE3843126C3 (de) * 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
ES2057191T5 (es) * 1989-01-13 2003-05-01 Mitsubishi Pharma Corp Metodo de produccion para una composicion que contiene proteinas.
FR2644476A1 (fr) * 1989-03-15 1990-09-21 Sainte Agathe Nicolas De Procede de detection et/ou d'identification de micro-organismes vivants par vibrometrie
FR2658517B2 (fr) * 1989-04-12 1992-06-19 Fondation Nale Transfusion San Preparation de la proteine c activee et solution de proteine c activee ainsi obtenue.
DK0431129T3 (da) * 1989-06-15 1996-06-17 Rorer Int Overseas Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater
AT402153B (de) * 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
PT95193A (pt) * 1989-09-05 1991-05-22 Lilly Co Eli Metodo para actividade da proteina c
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
JPH0564588A (ja) * 1991-08-14 1993-03-19 Teijin Ltd 短い重鎖を有するヒトプロテインｃおよび活性化ヒトプロテインｃ
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
AT398079B (de) * 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JP3429433B2 (ja) * 1997-06-18 2003-07-22 松本建工株式会社 鉄骨造建築物に於ける冷橋防止構造
FR2841484B1 (fr) * 2002-06-26 2004-09-10 Boucq De Beaudignies Ghisla Le Dispositif et procede de filtration de l'air et des gaz avec regeneration des particules captees

Also Published As

Publication number Publication date
CZ148294A3 (en) 1995-01-18
FI942941L (fi) 1994-12-19
JP3106059B2 (ja) 2000-11-06
HUT67074A (en) 1995-01-30
ES2162829T3 (es) 2002-01-16
EP0629407A2 (de) 1994-12-21
HU9401817D0 (en) 1994-09-28
SK282358B6 (sk) 2002-01-07
FI942941A7 (fi) 1994-12-19
CA2126135A1 (en) 1994-12-19
CA2126135C (en) 2002-02-19
DK0629407T3 (da) 2001-11-12
DE4320294A1 (de) 1994-12-22
HU217609B (hu) 2000-03-28
AU6471994A (en) 1994-12-22
DE69428231T2 (de) 2002-06-13
DE69428231D1 (de) 2001-10-18
FI942941A0 (fi) 1994-06-17
JPH0748275A (ja) 1995-02-21
AT407704B (de) 2001-05-25
ATA119394A (de) 2000-10-15
SK74894A3 (en) 1995-05-10
NO942298D0 (no) 1994-06-17
EP0629407A3 (de) 1995-05-24
US5614493A (en) 1997-03-25
NO942298L (no) 1994-12-19
AU680894B2 (en) 1997-08-14
EP0629407B1 (de) 2001-09-12

Similar Documents

Publication Publication Date Title
ATE74282T1 (de) Methode zur behandlung von plasma und dessen produkten.
DE59410094D1 (de) Vorrichtung zur behandlung von biologischem gewebe und körperkonkrementen
ATE300298T1 (de) Behandlung von leukocyten durch photopheresis
ATE302599T1 (de) Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
DE59600309D1 (de) Vorrichtung zur Behandlung von Flüssigkeiten, insbesondere von Blut
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
ATE205396T1 (de) Verwendung von menschlichem protein c zur verhinderung und behandlung von ablagerungen von thrombocyten
DE69314590D1 (de) Behandlung von Proteinhaltigen Körperflüssigkeiten
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ATE69163T1 (de) Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen.
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
DE68908404D1 (de) Lang haltende zusammensetzung von propafenon und chinidin zur behandlung des zustandes des herzens.
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE96039T1 (de) Arzneimittel und ihre verwendung zur behandlung von parasitosen.
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE59408477D1 (de) Therapieeinrichtung zur behandlung von leiden des herzens und herznaher gefässe

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee